Among 226 MDMA users, 11.5% met lifetime criteria for Major Depressive Disorder. No association was found between the number of MDMA uses and major depression. However, those with lifetime major depression had higher rates of lifetime cannabis use disorder (adjusted odds ratio 2.40). Logistic regression indicated that lifetime cannabis use disorder, but not MDMA use, was significantly associated with lifetime Major Depressive Disorder. For females, a lifetime cannabis use disorder was strongly associated with major depression (adjusted odds ratio 4.99), while for males, neither drug use variable was associated with major depression.
Adolescents use a wide variety of club drugs and other abusable substances, including both well-known and newly custom-designed compounds, which pose high potential for acute and chronic direct and interactive effects. The article reviews dextromethorphan, flunitrazepam (Rohypnol), gamma-hydroxybutyrate, inhalants, ketamine, lysergic acid diethylamide, methylenedioxymethamphetamine, phencyclidine, Salvia divinorum (salvia), synthetic cannabinoids, and synthetic cathinones (bath salts). It emphasizes the need for vigilance in anticipating and recognizing new effects and drug-drug interactions as novel substances continue to be manufactured and marketed to meet substance use trends.